Sutimlimab in Cold Agglutinin Disease

2021199 citationsJournal Articlebronze Open Access

Authors

Alexander Röth · University of Duisburg-Essen

Wilma Barcellini · Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

Shirley D’Sa · National Health Service

Yoshitaka Miyakawa · Saitama Medical University Hospital

Catherine M. Broome · MedStar Georgetown University Hospital

Marc Michel · Assistance Publique – Hôpitaux de Paris

David J. Kuter

Abstract

In patients with cold agglutinin disease who received sutimlimab, selective upstream inhibition of activity in the classic complement pathway rapidly halted hemolysis, increased hemoglobin levels, and reduced fatigue. (Funded by Sanofi; CARDINAL ClinicalTrials.gov number, NCT03347396.).

Topics & Keywords

Blood groups and transfusion Erythrocyte Function and Pathophysiology Complement system in diseases

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 384, Issue 14, pp. 1323-1334

DOI: 10.1056/nejmoa2027760

Field-Weighted Citation Impact: 21.61